Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Humanigen Inc. | Lenzilumab - (ACTIV-5/BET-B) | COVID-19 | Phase 2/3 | Intravenous | COVID-19 | |
| HUTCHMED (China) Limited | HMPL-523 - (ESLIM-01) | Primary immune thrombocytopenia (ITP) | Phase 3 | Data Released | Oral | Hematology |
| HUTCHMED (China) Limited | HMPL-523 - (ESLIM-01) | Primary immune thrombocytopenia (ITP) | Phase 3 | Data Released | Oral | Hematology |
| HUTCHMED (China) Limited | Surufatinib and Toripalimab | Solid Tumors | Phase 2 | Trial Completed | Oral for Surufatinib intravenous for Toripalimab | Oncology |
| HUTCHMED (China) Limited | Fruquintinib and Paclitaxel - (FRUTIGA) | Gastric Cancer | Phase 3 | Data Released | Oral and intravenous | Oncology |
| HUTCHMED (China) Limited | HMPL-453 | Mesothelioma | Phase 2 | Trial Completed | Oral | Oncology |
| HUTCHMED (China) Limited | ORPATHYS (savolitinib) and TAGRISSO (osimertinib) - (SANOVO) | First-line treatment in certain non-small cell lung cancer (NSCLC) | Phase 3 | Enrollment Conclusion | Oral | Oncology |
| HUTCHMED (China) Limited | SULANDA (surufatinib) and TUOYI (toripalimab) - (SURTORI-01) | Neuroendocrine carcinoma | Phase 3 | Ongoing | Oral for SULANDA surufatinib intravenous for TUOYI toripalimab | Oncology |
